MTVA 最新10-Q变化
将 MTVA 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-06 与上一份 10-Q · 2026-05-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +32 | −22 | ~9 | 15 |
| 控制与程序 | 文字有新增/删除 | +2 | −2 | ~1 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-06
●April 2026: Dosed the first patient in the Phase 1, Part 3 clinical trial for DA-1726 in obese, otherwise healthy adults using one-step titration to 48 mg and two-step titration to 64 mg to safely achieve higher target doses and optimize tolerability.
●May 2026: Presented additional data from the 48 mg Phase 1 clinical trial of DA-1726 at the European Association for the Study of the Liver Congress 2026 (EASL 2026), which was held May 27-30 in Barcelona, Spain, demonstrating up to 9.1% mean body weight reduction without evidence of plateau and ex…
●June 2026: Presented new late-breaking data at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, which was held in New Orleans, Louisiana, United States, supporting DA-1726's differentiated obesity profile and demonstrating the combination potential of vanoglipel with resmetirom i…
●July 2026: Announced the completion of dose titration in the 16-week, Phase 1 Part 3 study of DA-1726, with all active patients successfully reaching the highest planned dose levels of 48 mg and 64 mg.
(Loss) gain from change in fair value of warrant liabilities
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Certain amounts in the following discussion and analysis may not add up due to rounding, and all percentages have been calculated using unrounded amounts.
●January 2026: Announced positive statistically significant results from the eight-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort of the Phase 1 clinical trial for DA-1726.
●January 2026: Closed on an underwritten public offering and received net proceeds of $7.1 million.
●March 2026: Announced that the Institutional Review Board at Clinical Pharmacology of Miami has approved our Phase 1, Part 3 clinical trial for DA-1726.
●April 2026: Dosed the first patient in the Phase 1, Part 3 clinical trial for DA-1726.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-06
Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
相对上期删除的文字 · 来源:10-Q · 2026-05-14
There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2026 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议